Results

Total Results: 1,544 records

Showing results for "drug".

321. App-D-Opioid-Chronic-Pain-Surveill-Report-1 (xls file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
     September 30, 2015 - the trial did not indicate clear differences between treatments for pain, functioning, depression, or drug … Excluded patients with history of psychosis Substance use: Excluded patients with history of illicit drug … months followup Inclusion: Insured patients ≥65 years with osteoarthritis and continuous medical and drug … applicable; NR = not reported; NRS = numeric rating scale; NSAID = non-steroidal anti-inflammatory drug … ; OAT = opioid agonist therapy; OR = odds ratio; OUD = opioid use disorder; PDMP = prescription drug

322. Atrial-Fibrillation Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation_executive.pdf
     June 01, 2013 - Although the ongoing Catheter Ablation versus Antiarrhythmic Drug Therapy for AF (CABANA) study will … We used several approaches to identify relevant gray literature, including requests to drug and device … We grouped interventions by drug class; in this context, we considered all non-dihydropyridine calcium … enhancement of external electrical cardioversion vs. no drug enhancement SOE = Moderate (2 studies … While data suggest that drug pretreatment enhances electrical cardioversion in terms of restoration

323. #06 Developmental Delays ADHD, and Autism (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/developmental-delays-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … MG01CI is an extended-release version of metadoxine, a drug originally prescribed for treating acute

324. Research White Paper Multinational Registries Addendum Registries for Evaluating Patient Outcomes Third Edition (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/multinational-registries-guide-3rd-ed-addendum-white-paper.pdf
     February 01, 2018 - For example, in a drug exposure registry in which the drug is new to market, patient enrollment into … the registry is dependent upon drug access and reimbursement as well as market uptake of the drug. … For a given drug, any or all of these factors could vary by country. … Pharmacoepidemiol Drug Saf. 2008 Feb;17(2):200-8. PMID: 17868186. 35. … Food and Drug Administration. Guidance for Industry.

325. Crosscutting-Horizon-Scan-High-Impact-1506 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/crosscutting-horizon-scan-high-impact-1506.pdf
     June 01, 2015 - Food and Drug Administration (FDA) in May 2013. … Once activated, the sensor transmits digital information regarding the drug taken, its dose, and … Food and Drug Administration (FDA). 510(k) summary for Raisin personal monitor [K093976]. … Food and Drug Administration (FDA); 2010 Mar 25 [accessed 2010 Dec 27]. [10 p]. … Food and Drug Administration (FDA); 2012 May 14. 10 p.

326. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetes-horizon-scan-high-impact-1412.pdf
     January 01, 2015 - Food and Drug Administration (FDA). … Food and Drug Administration (FDA); 2012 Nov 9. 63 p. … Food and Drug Administration (FDA); 2013 Sep 26. 54 p. … Food and Drug Administration (FDA). … Food and Drug Administration (FDA); 2011 Dec 6. 64 p. 30.

327. S23 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s23.pdf
     October 01, 2007 - conducted by a group of independent researchers from Yale University with help from the US Food and Drug … The chance of experiencing stroke was almost never discussed with this drug and only odds ratios were … In this in- stance, the drug was taken off the market. … Decisions on drug therapies by numbers needed to treat: a randomized trial. … FDA Approves New Drug to Reduce Risk of Stroke. 1999.

328. Diabetes Mellitus (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/07_diabetes_potential_high_impact_june_2012.pdf
     January 01, 2012 - Food and Drug Administration (FDA) treatment investigational new drug program to patients in the United … Food and Drug Administration (FDA) guideline for CLS studies. … Food and Drug Administration (FDA); 2011 Dec 1 [accessed 2012 Apr 10]. [2 p]. … Food and Drug Administration (FDA); 2011 Dec 1 [accessed 2011 Dec 15]. [2 p]. … Food and Drug Administration (FDA); 2011 Feb 16 [accessed 2011 May 23]. [2 p].

329. DEMENTIA INCLUDING ALZHEIMER'S #04 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/dementia-horizon-scan-high-impact-1412.pdf
     February 01, 2015 - similar drugs in the same class are read separately), and then topics in the same class of a device, drug … Food and Drug Administration (FDA) for antidepressant use. … Food and Drug Administration (FDA) treat only AD symptoms; they are not disease-modifying. … -based online aggregator of prescription-drug prices found prices between $25 and $250 for a single … Some of the experts believe that as a potentially affordable, easily administered drug, intranasal

330. Maternal and Fetal Effects of Mental Health Treatments in Pregnant and Breastfeeding Women: A Systematic Review of Pharmacological Interventions (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/protocol-pharm-pregnant-women_0.pdf
     December 05, 2018 - Designing drug trials: considerations for pregnant women. … Food and Drug Administration. … Pharmacoepidemiol Drug Saf. 2013 Sep;22(9):1013-8. doi: 10.1002/pds.3495. PMID: 23893932. 30. … Allergies" OR "Drug Dependency" OR "drug effects" OR "Drug Sensitivity" OR harm* OR harms OR "Long … Therapy"[Mesh] OR "drug therapy"[Subheading] OR drug*[tiab] OR pharmacotherap*[tiab] OR pharmacologic

331. S1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s1.pdf
     October 01, 2007 - The Part D drug benefit is in the forefront of this interest because the appropriate use of medications … Nevertheless, expanded access and use of drug therapies also holds the potential for poor outcomes resulting … from the adverse drug effects of medications, suboptimal treatment response, inappropriate choice of

332. Pneumonia-Antibiotic-Treatment Executive (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/pneumonia-antibiotic-treatment_executive.pdf
     November 01, 2014 - Intravenous antibiotics for which PK/PD measures could be used Drug Class Drug Subclass Druga Aminoglycosides … PK is the study of the time course of drug absorption, distribution, metabolism, and excretion. … Optimizing drug exposure to minimize selection of antibiotic resistance. … Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. … Clin Drug Invest. 1999(2):133-9. 30. Hanes SD, Wood GC, Herring V, et al.

333. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1512.pdf
     December 01, 2015 - Drug Enforcement Administration, which classifies it as a Schedule III drug requiring a license and … Drug Enforcement Administration license.39,40 High-dose ketamine can be abused as a street drug known … Biopharm Drug Dispos. 2003 Jan;24(1):37-43. … Drug Enforcement Administration. … Research suggests new drug targets for depression.

334. Living Systematic Review on Plant-Based Treatment for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/plant-based-treatments-revised-protocol.pdf
     March 29, 2023 - Annual Surveillance Report of Drug-Related Risks and Outcomes--United States, 2017. … https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-report.pdf. 8. … Drug Abuse Warning Network. … The DAWN Report: Highlights of the 2010 Drug Abuse Warning Network (DAWN) findings on drug-related emergency … The aspirin story - from willow to wonder drug.

335. Disposition of Comments: CER 228, Nonopioid Pharmacologic Treatments for Chronic Pain (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cer-228-nonopioid-pharm-chronic-pain-comments.pdf
     April 16, 2020 - However, the mass hysteria over a non existent "prescription drug crisis"; will eventually come to … In addition, it does not appropriately balance the use of nonopioid drug regimens against patients’ … More importantly, nonopioid drug therapies are not necessarily a replacement for the use of opioids … (i.e., the opioid's duration of action, the parent opioid compound, presence of chronic pain, and drug … chronic pain, varying by pain population (e.g. neuropathic pain, fibromyalgia, etc.) and nonopioid drug

336. CARDIOVASCULAR (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/cardiovascular-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - The drawbacks include nonhemorrhagic side effects, potential drug-drug interactions, and the fact that … warfarin, these therapies have other drawbacks, including nonhemorrhagic side effects, potential for drug-drug … Food and Drug Administration (FDA). … Drug coverage guidelines: Juxtapid. [internet]. … Food and Drug Administration (FDA).

337. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - itself: Coffey et al, Mortality associated with implantation and management of intrathecal opioid drug … We are no longer analyzing anticonvulsants together as a drug class, but are only analyzing comparison … If the more modern studies on pregabalin are mostly negative, why would you conclude that this drug … WITH GABAPENITIN ALTHOUGH THERE ARE A LOT OF REPORTED PATIENT SIDE EFFECTS WITH DULOXETINE , the drug … For head to head trials, we have now taken out evaluations of anticonvulsants as a drug class since

338. Preventing Complications and Treating Symptoms of Diabetic Peripheral Neuropathy (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/diabetic-neuropathy-disposition-170707.pdf
     March 24, 2017 - itself: Coffey et al, Mortality associated with implantation and management of intrathecal opioid drug … We are no longer analyzing anticonvulsants together as a drug class, but are only analyzing comparison … If the more modern studies on pregabalin are mostly negative, why would you conclude that this drug … WITH GABAPENITIN ALTHOUGH THERE ARE A LOT OF REPORTED PATIENT SIDE EFFECTS WITH DULOXETINE , the drug … For head to head trials, we have now taken out evaluations of anticonvulsants as a drug class since

339. #05 DEPRESSION (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/depression-horizon-scan-high-impact-1412.pdf
     December 01, 2014 - Drug Enforcement Administration classifies ketamine as a Schedule III drug, requiring a license and … Drug Enforcement Administration. … Research suggests new drug targets for depression. … Washington (DC): Drug Enforcement Administration, U.S. … Food and Drug Administration (FDA) [accessed 2013 Aug 19]. [2 p].

340. Observed Association Between Antidepressant Use and Pneumonia Risk Was Confounded by Comorbidity Measures (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/antidepressants-seniors-pneumonia_research.pdf
     May 01, 2008 - implicated as risk factors for pneumonia, including chronic neurologic and pulmonary conditions [4]), drug … to 1.99) 10 * Adjusted for age, sex, calendar year, and current use of an antidepressant drug … to 7.85) 12 * Adjusted for age, sex, calendar year, and current use of an antidepressant drug